Learning Objectives
Upon completion of this education program the participant should be able to:

• Identify the indications for treatment of Multiple Myeloma as well as factors impacting prognosis;
• Identify and discuss factors that put patients at risk for complications of their disease and its treatment;
• Cite and summarize the major clinical trials that support use of the various approved pharmaceutical agents in Multiple Myeloma;
• Discuss and appraise the role of autologous and non-myeloablative allogeneic stem cell transplantation in Multiple Myeloma;
• Describe and differentiate treatment options for relapsed and refractory Multiple Myeloma.

Target Audience
This learning activity is intended for medical oncologists, hematologists, stem cell transplant physicians, and other interested healthcare professionals who treat and manage myeloma and related diseases in the hematology/oncology and transplant patient settings.